Nyheter

Sensational Enhancement

SPAGO Imaging has now confirmed that the relaxivity (t1)of our nanoparticles is reliably more than 50/mmol Gd/s (at 2 T) as compared to the marketed contrast agents hovering around 4/mmol Gd/s. The relaxivity determines how much the MRI images are enhanced. In combination with the large number of gadolinium ions…
Läs mer

SPAGO i Veckans Affärer

SPAGO Imaging AB omnämns positivt i Veckans Affärer, http://www.va.se/nyheter/2010/03/25/framkantsteknik-till-fyndpris/.
Läs mer

New recruit to the Board of Directors

SPAGO Imaging has recruited Jörgen Buus Lassen to the Board of Directors. Jörgen Buus Lassen D.V.M. has over 25 years of experience in pharmaceutical research. He is a co-founder and former CEO of NeuroSearch, a Danish pharmaceutical company with a stock market value of approximately SEK 5.5 billion (2010-03-12).
Läs mer

New Head of Business Development

SPAGO Imaging has recruited Allan Simpson as Head of Business Development. Allan Simpson has a background from GE Healthcare where he have been Director of Strategic Alliances and Vice President of Research & Analysis Marketing.
Läs mer

Professor Sven Lidin joins the Scientific Advisory Board

Professor Sven Lidin joins the Scientific Advisory Board of SPAGO Imaging.
Läs mer

Proof-of-Concept studies completed

SPAGO Imaging completes successful Proof-of-Concept studies in a tumor model.
Läs mer

New Senior Research Scientist

SPAGO Imaging recruits Dr Fredrik Ek as Senior Research Scientist.
Läs mer

SPAGO signs agreement

SPAGO Imaging signs agreement of cooperation with Nano-h.
Läs mer

Move to new labs

SPAGO Imaging moves to new labs in Lund Bioinkubator.
Läs mer

New CTO

Dr Oskar Axelsson is recruited as CTO to Spago Imaging.
Läs mer